共被期刊论文引用了2次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Risk factor analysis of perioperative mortality after ruptured bleeding in hepatocellular carcinoma显示文摘AIM:To discuss strategies and prognosis for the emergency treatment of ruptured bleeding in primary hepatocellular carcinoma.METHODS:The retrospective analysis was performed by examining the emergency treatment experiences of60 cases of ruptured bleeding in primary hepatocellular carcinoma.The treatment methods included surgical tumour resection,transcatheter arterial embolization(TAE)and non-surgical treatment.Univariate and multivariate analyses were performed to identify the risk factors that impacted 30-d mortality in the research groups.RESULTS:The 30-d mortality of all patients was 28.3%(n=17).The univariate analysis showed that ChildPugh C level liver function,shock,massive blood transfusion and large tumour volume were risk factors thatinfluenced 30-d mortality.The multivariate analysis showed that shock and massive blood transfusion were independent risk factors that impacted the 30-d mortality of surgical resection.As for the TAE patients,larger tumour volume was a risk factor towards prognosis.CONCLUSION:Radical resection and TAE therapy would achieve better results in carefully selected ruptured hepatocellular tumours. | Hao-Ming Lin Li-Ming Lei Jie Zhu Guo-Lin Li Jun Min | 2014 | World Journal of Gastroenterology2014，20，40： | 10 |
| 2 | Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture显示文摘AIM:To report the outcome of patients with ruptured hepatocellular carcinoma(HCC)treated at a single center during a 5-year period.METHODS:We retrospectively analyzed 32 patients who presented with ruptured HCC at Shandong Provincial Hospital Affiliated to Shandong University between2008 and 2013.RESULTS:The mean age of the patients was 53 years(range 39-71 years).Of these patients,22 received surgical management,10 underwent transarterial embolization(TAE)or transarterial chemoembolization(TACE),and 12 received sorafenib after surgery,TAE or TACE.Cumulative survival rates at 4,8 and 12 mo were72.9%,50.0%and 33.3%,respectively,in the surgery only group and were 90.0%,80.6%and 64.1%,respectively,in the surgery plus sorafenib group.Cumulative survival rates at 4,8 and 12 mo were 68.4%,43.6%and 19.4%,respectively,in the surgery only or TAE/TACE only groups,and were 91.7%,75.0%and 60.2%,respectively,in the sorafenib combination groups(P=0.04).No unexpected side effects due to sorafenib were observed.The most common side effect was hand-foot skin reaction.To date,5 patients have died.Median follow-up from the start of sorafenib therapy for the remaining 7 patients is 12.7 mo(range5.8-32.2 mo).CONCLUSION:Sorafenib can be used in patients with ruptured HCC as it has interesting activity and is well tolerated;dose adjustment is generally not required.However,a larger prospective study is necessary to determine the efficacy of sorafenib in this group of patients. | Shun-Zhen Zheng De-Jie Liu Ping Sun Guang-Sheng Yu Yan-Tian Xu Wei Gong Jun Liu | 2014 | World Journal of Gastroenterology2014，20，43： | 8 |
您所在的机构暂未开通此部分的功能，请联系管理员